Longboard Pharmaceuticals

Lundbeck to acquire Longboard Pharmaceuticals, gaining access to bexicaserin, a promising 5-HT2C receptor agonist for treating rare developmental epileptic encephalopathies. The deal includes a tender offer of $2.6 million per share and integration costs of $80 million.

Lundbeck agreed to acquire Longboard Pharmaceuticals for US$2.6 billion, offering US$60 per share in cash to boost its drug pipeline for serious brain diseases. Longboard's main drug, bexicaserin, shows potential for treating rare epilepsies. The deal is expected to close in Q4, funded by existing cash and bank financing.

Lundbeck to acquire Longboard Pharmaceuticals for $2.6B, enhancing its neuroscience pipeline with bexicaserin, a late-stage treatment for Developmental and Epileptic Encephalopathies (DEEs). The acquisition aligns with Lundbeck’s Focused Innovator strategy and aims to address high unmet medical needs in neuro-rare conditions. Bexicaserin, a 5-HT2C receptor superagonist, has shown promising anti-seizure effects and is in a global phase III trial for Dravet syndrome.

Lundbeck to acquire Longboard Pharmaceuticals for $2.6 billion in cash.

Longboard Pharmaceuticals initiated a Phase 3 DEEp SEA trial to evaluate bexicaserin's efficacy and safety for Dravet syndrome and other DEEs, enrolling 160 patients aged 2-65. Bexicaserin, granted orphan drug and rare pediatric disease designations by the FDA, aims to reduce seizure frequency by targeting the 5-HT2C receptor. The trial includes a three-month treatment period with an optional yearlong extension.

Longboard Pharmaceuticals has initiated the international Phase III DEEp SEA Study of bexicaserin (LP352) for treating seizures in Dravet syndrome patients. The placebo-controlled, double-blind trial will enrol approximately 160 subjects aged 2-65 years, aiming to evaluate bexicaserin's efficacy in reducing countable motor seizures, with safety and tolerability as key secondary goals. The study involves a five-week screening and baseline period, followed by a three-week dose titration and 12-week maintenance phase. Eligible participants can enrol in the 52-week DEEp Open-Label Extension after the maintenance phase. Bexitaserin, an oral 5-HT2C receptor superagonist, previously received breakthrough therapy designation from the US FDA for treating seizures in developmental and epileptic encephalopathies (DEEs) in patients aged two years and older.

Longboard Pharmaceuticals initiates global Phase 3 DEEp SEA Study evaluating bexicaserin for Dravet syndrome, with first sites activated and more to follow.

Longboard Pharmaceuticals receives FDA's Rare Pediatric Disease and Orphan Drug designations for bexicaserin in Dravet syndrome, with potential for a Priority Review Voucher.